AU9470735

(12) PATENT ABRIDGMENT (11) Document No. AU-B-70735/94
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 698928

(54) Title
METHYLPHOSPHONIC ACID ESTER, PROCESS FOR PREPARING THE SAME AND ITS USE

International Patent Classification(s)
(51)[6] **C07H 021/00** **A61K 031/70**

(21) Application No. : **70735/94** (22) Application Date : **29.06.94**

(87) PCT Publication Number : **WO95/01363**

(30) Priority Data

(31) Number	(32) Date	(33) Country
4321946	**01.07.93**	**DE GERMANY**

(43) Publication Date : **24.01.95**

(44) Publication Date of Accepted Application : **12.11.98**

(71) Applicant(s)
HOECHST AKTIENGESELLSCHAFT

(72) Inventor(s)
EUGEN UHLMANN; CHRIS MEIER

(74) Attorney or Agent
WATERMARK PATENT & TRADEMARK ATTORNEYS , Locked Bag 5, HAWTHORN VIC 3122

(56) Prior Art Documents
WO 93/10140
ROELEN M ET AL TETRAHEDRON LETTERS 33(17) 1992 P 2357-2360
MEIER C ET AL BIOORG MED CHEM LETTERS 2(10) 1991 P 527-530

(57) Claim

1. Compounds of the formula I,



(I)

characterized in that

Y has the meaning of OH, SH, OAc or SAc, where Ac= (C1-C18)-acyl, which is optionally unsaturated 1-3 times,

R' is an aryl group having n carbon atoms which can be substituted or unsubstituted; or

an alkyl group having n carbon atoms, which can be branched or unbranched, substituted or unsubstituted; or a heteroaryl group which can have heteroatoms selected from the group including N,O and S, where n = any number of carbon atoms.

W has the meaning of a pharmaceutical active compound radical,

R has the meaning of W, where R and W can be identical or different, or R is an optionally substituted alkyl radical or

.../2

W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'



(II)



(II')

where X is oxy, sulphanediyl or methylene,

B independently of one another is a nucleotide base,

n independently of one another is an integer from 0 to 50,

R^1 and R^2 independently of one another are H (C1-C18) acyl or a radical of the formula



in which R^4 is O-, S-, CH_3 or CHYR', where R' and Y are as defined above and

R^5 is an optionally substituted alkyl radical having 1-18 carbon atoms,

R^3 is independently of one another H, O(C1-C18)-alkyl, O(C1-C18)-acyl, F, Cl, N_3, NH_2 or NHR^6 where R^6 is (C1-C6) - alkyl or -acyl

and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

7. Use of an oligonucleotide analogue according to any one of Claims 1 to 5 as an inhibitor of gene expression.

8. Pharmaceuticals, containing one or more of the compounds of the formula I according to any one of Claims 1-5.

10. A method according to Claim 10 wherein said pharmaceutical has a prodrug function.

PT DATE 24/01/95 APPLN. ID 70735/94
AOJP DATE 09/03/95 PCT NUMBER PCT/EP94/02121

AU9470735

(51) Internationale Patentklassifikation 6 : C07H 21/00, A61K 31/70

A1

(11) Internationale Veröffentlichungsnummer: WO 95/01363

(43) Internationales Veröffentlichungsdatum: 12. Januar 1995 (12.01.95)

(21) Internationales Aktenzeichen: PCT/EP94/02121

(22) Internationales Anmeldedatum: 29. Juni 1994 (29.06.94)

(30) Prioritätsdaten:
P 43 21 946.2 1. Juli 1993 (01.07.93) DE

(71) Anmelder (*für alle Bestimmungsstaaten ausser US*): HOECHST AKTIENGESELLSCHAFT [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt am Main (DE).

(72) Erfinder; und
(75) Erfinder/Anmelder (*nur für US*): UHLMANN, Eugen [DE/DE]; Zum Talblick 31, D-61479 Glashütten (DE). MEIER, Chris [DE/DE]; Ahlweg 11, D-61352 Bad Homburg (DE).

(81) Bestimmungsstaaten: AU, CA, FI, JP, NO, US, europäisches Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Veröffentlicht
Mit internationalem Recherchenbericht.
Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Änderungen eintreffen.

(54) Title: METHYLPHOSPHONIC ACID ESTER, PROCESS FOR PREPARING THE SAME AND ITS USE

(54) Bezeichnung: METHYLPHOSPHONSÄUREESTER, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG

(57) Abstract

Compounds having the formula (I), in which the substituents R', Y, W and R have the meanings cited, have in vivo the activity of the active substance residue W with improved pharmacokinetics.



(I)

(57) Zusammenfassung

Aus den Verbindungen der Formel (I), in der die Substituenten R', Y, W und R die genannten Bedeutungen haben, weisen in vivo die Wirkung des Wirkstoffrestes W bei verbesserter Pharmakokinetik auf.



Description

Methylphosphonic acid esters, processes for their preparation, and their use

The present invention relates to methylphosphonic acid esters, processes for their preparation, and their use.

Phosphorylated active compound derivatives are already known which have in some cases also been employed for pharmaceutical purposes. Thus, for example, in J. Med. Chem. 1993, 36, 1048-1052 phosphoamidate esters with AZT are described. The antiviral activity of these compounds, however, is less than that of AZT by the factor 10 and the toxicity of the compounds mentioned is higher than that of AZT by the factor 5. In J. Med. Chem. 1991, 34, 1830-1837, phosphotriester derivatives with AZT are described; in these compounds too the activity is lower and the toxicity greater than in the case of AZT. Similar results are obtained with related compounds, which are reported in J. Org. Chem. 1992, 57, 7300-7307.

With the intention of obtaining phosphorylated active compound derivatives which do not have the disadvantages of relevant prior art compounds, it has now been found that the methylphosphonic acid esters according to the invention have outstanding properties. The invention accordingly relates to

1) compounds of the formula I,



(I) .

characterized in that
Y has the meaning of OH, SH, OAc or SAc, where Ac=(C1-C18)-acyl, which is optionally unsaturated 1-3 times,

R' is an aryl group having n carbon atoms, which can be substituted or unsubstituted; or

an alkyl group having n carbon atoms, which can be branched or unbranched, substituted or unsubstituted; or a heteroaryl group which can have heteroatoms selected from the group including N,O and S, where n = any number of carbon atoms.

W has the meaning of a pharmaceutical active compound radical,

R has the meaning of W, where R and W can be identical or different, or R is an optionally substituted alkyl radical or

W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'



(II)



(II')

where X is oxy, sulphanediyl or methylene,

B independently of one another is a nucleotide base,

n independently of one another is an integer from 0 to 50,

R^1 and R^2 independently of one another are H (C1-C18) acyl or a radical of the formula



in which R^4 is O-, S-, CH_3 or CHYR', where R' and Y are as defined above and

R^5 is an optionally substituted alkyl radical having 1-18 carbon atoms,

R^3 is independently of one another H, O(C1-C18)-alkyl, O(C1-C18)-acyl, F, Cl, N_3, NH_2 or NHR^6 where

AUSTRALIAN PATENT OFFICE

R^6 is (C1-C6)-alkyl or -acyl
and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

2. Preferred compounds of the formula I are as elucidated under 1),
characterized in that
Y has the meaning of OH, SH, OAc or SAc, where Ac = (C1-C8)-acyl, which is optionally unsaturated 1-3 times,
R' is aryl having 6-14 carbon atoms, optionally substituted by up to three radicals which are independent of one another, selected from the group consisting of
(C1-C5)-alkyl, halogen, NO_2, CN, (C1-C6)-alkoxy, amino, (C1-C4)-alkylamino, (C1-C8)-dialkylamino, where a (C3-C8)-alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 13 carbon atoms and up to 3 heteroatoms selected from the group consisting of N, O and S;
(C1-C16)-alkyl, which is branched or unbranched, saturated or unsaturated 1-3 times, optionally substituted independently of one another by up to three substituents selected from the group consisting of halogen, CN, NO_2 and (C1-C3)-alkoxy,
W has the meaning of a pharmaceutical active compound radical,
R has the meaning of W, where R and W can be identical or different, or R is (C1-C16)-
alkyl, which can be branched or unbranched and is optionally substituted independently of one another by up to 3 radicals from the group consisting of halogen, CN, (C1-C8)-acyloxy, (C1-C18)-alkoxy or
W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the

AUSTRALIAN PATENT OFFICE

formula II'
where X is oxy or sulphanediyl,
B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 30,
R^1 and R^2 independently of one another are H (C1-C12)-acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-12 carbon atoms,
R^3 independently of one another is H, O(C1-C12)-alkyl, O(C1-C12)-acyl, Cl, N_3, NH_2 or NHR^6 where R^6 is (C1-C3)-alkyl or -acyl
and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position,

3) Particularly preferred compounds of the formula I are as elucidated under 1) or 2),
characterized in that
Y has the meaning of OH, SH, OAc or SAc, where Ac = (C1-C3)-acyl, which is optionally unsaturated 1-3 times,
R' is aryl having 6-14 carbon atoms, optionally substituted by up to 3 radicals which are independent of one another, selected from the group consisting of
(C1-C3)-alkyl, F, Cl, NO_2, CN, (C1-C4)-alkoxy, amino, (C1-C3)-alkylamino, (C1-C6)-dialkylamino, where a (C3-C8)-alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 6 carbon atoms and up to 3 heteroatoms selected from the group consisting of N,

AUSTRALIAN PATENT OFFICE

O and S;
(C1-C8)-alkyl, which is branched or unbranched, saturated or unsaturated 1-3 times, optionally substituted independently of one another by up to three substituents selected from the group consisting of Cl, CN, NO_2 and (C1-C3)-alkoxy,
W has the meaning of a 5'-, 3' or 2' nucleoside analogue, of a steroid, of a sugar, of an inositol or of a peptide having at least one amino acid Ser or Tyr and a total of up to 20 natural amino acids,
R has the meaning of W or is (C1-C8)-alkyl, which can be branched or unbranched and is optionally substituted by up to 2 radicals from the group consisting of halogen, CN, (C3-C6)-acyloxy, (C8-C18)-alkoxy or
W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'
where X is oxy,
B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 20,
R^1 and R^2 independently of one another are H (C1-C8)-acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-8 carbon atoms,
R^3 independently of one another is H, O(C1-C8)-alkyl, O(C1-C8)-acyl, Cl or N_3, and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

4) Very particularly preferred compounds of the formula

I are as elucidated above under 1) to 3),
characterized in that
Y has the meaning of OH,
R' is aryl having 6 carbon atoms, optionally substituted by up to 3 radicals which are independent of one another, selected from the group consisting of (C1-C3)-alkyl, F, Cl, NO_2, CN, (C1-C4)-alkoxy, amino, (C1-C3)-alkylamino, (C1-C6)-dialkylamino, where a (C3-C6)-alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 6 carbon atoms and up to 3 heteroatoms selected from the group consisting of N, O and S;
(C1-C8)-alkyl, which is branched or unbranched, saturated or unsaturated 1-3 times, preferably unsaturated in conjugated form having an unsaturated bond in the alpha-position, optionally substituted independently of one another by up to three substituents selected from the group consisting of Cl, CN, NO_2 and (C1-C3)-alkoxy,
W has the meaning of a 5'- or 3' nucleoside analogue,
R has the meaning of W or is (C1-C4)-alkyl, which can be branched or unbranched or
W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'
where X is oxy,
B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 15,
R^1 and R^2 independently of one another are H (C1-C4)-acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-3 carbon atoms,
R^3 independently of one another is H, O(C1-C3)-alkyl, O(C1-C3)-acyl, Cl or N_3, and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

5) Compounds of the formula I which are furthermore of particular importance are as elucidated under 1) to 4), characterized in that
Y has the meaning of OH,
W has the meaning of a 5'- or 3' nucleoside analogue,
R has the meaning of W or is (C1-C4)-alkyl, which can be branched or unbranched,
R' is aryl having 6 carbon atoms, optionally substituted by up to 3 radicals which are independent of one another, selected from the group consisting of Cl, NO_2, CN, (C1-C3)-alkoxy, amino and (C1-C3)-alkylamino.

The term "independently of one another" used above in connection with substituents which occur several times (e.g. "B") is intended to make it clear that in one compound in each case the particular substituents can be different, which also applies to elements repeating themselves n times.

Examples of acyl groups mentioned in the preceding definitions are acetyl, butyryl, pivaloyl, crotonoyl, pentanoyl, hexanoyl, octadecanoyl or oleyl.

Suitable alkyl groups are, for example, methyl, ethyl, propyl, butyl, isobutyl, pentyl or hexyl.

Exemplary aryl groups are phenyl or naphthyl.

Suitable heteroaryl groups are, for example, pyridyl,

oxazole, furyl, benzofuryl or phenothiazinyl.

Exemplary alkylamino groups are the methyl and the dimethylamino groups.

Exemplary dialkylamino groups are the dimethylamino and the diethylamino group.

Nucleoside analogues which are particularly suitable according to the invention are compounds derived from the bases adenine, cytosine, guanine, thymine, purine, 7-deazaadenine, 7-deazaguanine or 5-chlorocytosine, in particular, for example, 3'-deoxy-3'-azidothymidine, 2',3'-dideoxy-2',3'-didehydrothymidine, 2',3'-dideoxythymidine, 2'3'-dideoxyuridine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 3'F,3'-deoxythymidine, acyclovir and gancyclovir.

The abovementioned radicals R^5 can optionally be substituted by halogen, preferably Cl, CF_3, CN, NH_2 or (C1-C6)-preferably (C1-C3)-alkoxy.

The present invention furthermore relates to a process for the preparation of compounds according to one or more of Claims 1-5 which is characterized in that

a) a compound of the formula III is reacted with a compound of the formula IV,



(III)



(IV)

or in that

b) a compound of the formula V is reacted with compounds of the formula VI in any desired sequence and using a condensing agen.,

or in that

c) a compound of the formula V is reacted with compounds of the formula VI and of the formula VII in any desired sequence and using a condensing agent,



(V) , WOH (VI) , ROH (VII)

where SG is a protective group which is optionally removed to obtain the compound of the formula I,

or a nucleotide unit having a 3' (2')-terminal H-phosphonate group and protected 5'-hydroxy group is reacted with a further nucleotide unit having a free 5'-hydroxy group and protected 3'(2')-hydroxy group in the presence of an activating agent to give the H-phosphosphonate dinucleoside and this is condensed with an aldehyde to give the dinucleoside α-hydroxyalkyl(aryl)phosphonate, which after reaction to give its activated derivatives reacts with further (oligo)nucleotide fragments to give oligonucleotides, temporarily introduced protective groups being removed, or in that

a) a nucleotide unit having a 3'(2')-terminal phosphorus(III) or phosphorus(V) group is reacted with a free 5'-hydroxy group of a further nucleotide unit or growing oligonucleotide chain in the presence of a condensing agent or

b) its activated derivatives, or the oligonucleotide analogue is built up in fragments in the same way, protective groups temporarily introduced into the oligonucleotides obtained according to a) or b) for the protection of other functions are removed and the oligonucleotide analogues of the formula I thus obtained in which W is a radical of the formula II and R is a radical of the formula II' are optionally converted into their physiologically tolerable salt.

The reaction described under a) preferably proceeds under the following conditions.

A) Reaction of the phosphonate diester of the formula III with the appropriate substituted aldehydes of the formula IV in an organic solvent, e.g. in dry triethylamine (NEt_3) at elevated temperature, preferably at boiling heat.

B) Reaction of the phosphonate diester of the formula III with the aldehyde of the formula IV in a dry aprotic solvent, e.g. tetrahydrofuran (THF) with addition of an organic base, e.g. NEt_3 or quinine at room temperature ± 10°C.

After reaction is complete, the products are purified by known methods, e.g. by chromatography.

The reactions described in b) and c) proceed under conditions known for esterifications in the prior art. Particularly good results are achieved by means of intermediate active ester formation, for example with triazole/dimesitylenesulphonyl chloride.

Suitable protective groups which are optionally removed after the reaction according to methods of the prior art are, for example, alkylsilyl, alkylarylsilyl and acyl, in particular t-butyldimethylsilyl. The last-mentioned protective group can advantageously be removed using ammonium fluoride in methanol.

The compounds according to the invention can also be prepared stereoselectively according to various methods of the prior art. A preferred starting point for the introduction of the chirality on the α-carbon atom is the reaction of the C anion of a t-butyldimethylsilyl-protected alcohol (compound of the formula V) with the oxazaphospholidine derived from (+)-ephedrine as a chiral auxiliary. The oxazaphospholidine is obtained, for example, by reaction of phosphoryl chloride with (+)-ephedrine in 60 % yield and a diastereomer ratio of 24:1. A further possibility for the introduction of the chirality consists in the enantioselective oxaza-

borolidine-catalysed reduction (Tetrahedron Lett., 31, 611, (1990).

The starting substances needed for carrying out the abovementioned reactions are commercially available, or can be prepared according to generally known procedures. Some preferred preparation methods are described in the examples.

The nucleoside H-phosphonate diesters of the formula (III), which are used as starting compounds, can be prepared, for example, by the reaction of diisopropylaminedichlorophosphine with the corresponding nucleosides to give the phosphoramidite, which can be hydrolysed directly with tetrazole activation using water in a "one-pot reaction" to give the compounds of the formula III.

Alternatively, the synthesis takes place, for example, by the esterification of a 5'-nucleoside phosphorous acid monoester with a second equivalent of the nucleoside with pivaloyl chloride activation. A 5'-nucleoside phosphorous acid monoester is accessible by reaction of phosphorus trichloride with imidazole to give the phosphorus triimidazolide, after reaction with the corresponding nucleoside and subsequent hydrolysis.

Alternatively, the compounds of the formula III can be prepared by the esterification of a 5'-nucleoside phosphorous acid monoester with a second equivalent of the appropriate nucleoside with pivaloyl chloride activation.

The preparation of the compounds of the formula I having a radical of the formula II and II' is preferably carried out such that in principle dimeric nucleotides of the formula XI as described above are prepared, which are then incorporated into oligonucleotides by customary methods. For example (Scheme 1), a 5'-protected nucleoside 3'-H-phosphonate ester of the formula VIII can be reacted with a 3'-protected 5'-hydroxy component of the formula IX in the presence of a condensing agent such

AUSTRALIAN PATENT OFFICE

as pivaloyl chloride in pyridine to give the dinucleoside H-phosphonate ester of the formula X. This is then reacted with the appropriate aldehyde to give the dinucleoside hydroxyalkylphosphonate. The free α-hydroxy group must be protected for further reactions, preferably using the TBDMS (t-butyldimethylsilyl) protective group, which is removed at the end of the synthesis using fluoride ions. Formula XI compounds are reacted, for example after removal of the 3'-protective group (SG^2), to give the phosphoramidite of the formula XII, which can be introduced into oligonucleotides as analogues of the phosphoramidites according to known methods.

The prodrug nucleotides, however, can also be built up as monomeric units by condensation of appropriately protected nucleoside-3' (or 5')-phosphonate esters with the 5' (or 3'-)-hydroxy group of a 3' (or 5') protected nucleoside (Scheme 2). Preferably, the nucleoside -3'-phosphonamidates of the formula XIII (where (P) = P-N(ipropyl)$_2$) are used, which can be incorporated into oligonucleotides according to customary methods.

Oligonucleotide analogues of the formula I having a radical of the formula II or II' are prepared, similarly to the synthesis of biological oligonucleotides, in solution or preferably on solid phase, if appropriate with the aid of an automatic synthesis apparatus.

AUSTRALIAN PATENT OFFICE

Scheme 1



VIII IX X



XI

SG Reagent e.g. 

XII SG^1 = Dimethoxytrityl

SG^2 = 

AUSTRALIAN PATENT OFFICE

Scheme 2



SG^1, SG^2 = orthogonal protective groups

e.g. SG^1 = Dimethoxytrityl



e.g. SG^2 = Levulinoyl



CM = Condensing agent





acid-labile



The compounds of the formula I according to the invention and their pharmaceutically tolerable salts exhibit the pharmaceutical activity of the active compounds on which they are based. Since they additionally exhibit favourable toxicological and pharmacokinetic properties, they are useful chemotherapeutics.

The invention thus also relates to pharmaceuticals, in particular pharmaceuticals for the control of virus disorders, which are characterized in that they contain one or more of the compounds according to the invention. They can be administered, for example, orally, intramuscularly or intravenously.

Pharmaceuticals which contain one or more compounds of the general formula I as active compound can be prepared by mixing the compounds of the formula I with one or more pharmacologically tolerable excipients or diluents, such as, for example, buffer substances, and bringing them into a suitable preparation form.

Diluents which may be mentioned are, for example, polyglycols, ethanol and water. Buffer substances are, for example, organic compounds, such as N',N'-dibenzylethylenediamine, diethanolamine, ethylenediamine, N-methylglucamine, N-benzylphenethylamine, diethylamine, tris(hydroxymethyl)aminomethane, or inorganic compounds, such as phosphate buffer, sodium bicarbonate, sodium carbonate. For oral administration, suspensions or solutions in water with or without buffer substances are

preferably suitable. It is also possible to administer the active compounds as such without excipients or diluents in a suitable form, for example in capsules.

Suitable doses of the compounds of formula I or their pharmaceutically tolerable salts are highly dependent on the respective active compounds on which they are based; e.g. in the case of AZT they are approximately 0.4 g, preferably 0.5 g to at most 20 g per day for an adult of approximately 75 kg body weight. Individual or, in general, multiple doses can be administered, where the individual dose can contain the active compound in an amount from approximately 50 is 1000 mg.

The present invention furthermore relates to the use of the novel oligonucleotide analogues (compounds of the formula I having a radical of the formula II and II' as inhibitors of gene expression (anti-sense oligonucleotides, ribozymes, sense oligonucleotides and triplex forming oligonucleotides).
Oligonucleotides are used to a growing extent as inhibitors of gene expression (G. Zon, Pharmaceutical Research 5, 539 (1988); J.S. Cohen, Topics in Molecular and Structural Biology 12 (1989) Macmillan Press; C. Helene and J.J. Toulme, Biochemica and Biophysica Acta 1049, 99 (1990); E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). Anti-sense oligonucleotides are nucleic acid fragments whose base sequence is complementary to an mRNA to be inhibited. This target mRNA can be of cellular, viral or other pathogenic origin. Possible cellular target sequences are, for example, those of receptors, enzymes, immunomodulators, ion channels or oncogenes. The inhibition of virus replication with the aid of anti-sense oligonucleotides was described, for example, for RSV (Rous sarcoma virus), HSV-1 and -2 (herpes simplex virus type I and II), HIV (human immunodeficiency virus) and influenza viruses. In this case, oligonucleotides are employed which are complementary to the viral nucleic acid. Sense oligonucleotides, on the

AUSTRALIAN PATENT OFFICE

other hand, are designed in their sequence such that they bind ("capture"), for example, nucleic acid-binding proteins or nucleic acid-processing enzymes and thus inhibit their biological activity (Helene, 1990). Viral targets which may be mentioned here are, for example, reverse transcriptase, DNA polymerase and transactivator proteins. Triplex forming oligonucleotides in general have the DNA as a target and form a triple helical structure after binding to this. While with the aid of the anti-sense oligonucleotides the processing (splicing etc.) of the mRNA or its translation into the protein are in general inhibited, triplex forming oligonucleotides inhibit the transcription or replication of the DNA (Helene et al., 1990, Uhlmann and Peyman, 1990). However, it is also possible to bind single-stranded nucleic acids in a first hybridization with an anti-sense oligonucleotide with formation of a double strand, which then in a second hybridization with a triplex forming oligonucleotide forms a triplex structure. The anti-sense and triplex binding regions can in this case be accommodated either in two separate oligonucleotides or else in one oligonucleotide. A further application of synthetic oligonucleotides are the so-called ribozymes, which destroy the target RNA as a result of their ribonuclease activity (J.J. Rossi and N. Sarver, TIBTECH 8, 179 (1990).

For most applications mentioned, oligonucleotides are not very or completely unsuitable in their naturally occurring form. They must be modified chemically such that they fulfil the specific requirements. In order that oligonucleotides can be employed in biological systems, for example for the inhibition of virus replication, they must fulfil the following prerequisites:

1. They must have an adequate high stability under in vivo conditions, i.e. both in the serum and intracellularly.

2. They must be composed such that they can pass through the cell and nucleus membrane.

3. They must bind to their target nucleic acid under physiological conditions in a base-specific manner in order to display the inhibitory effect.

If the internucleotide phosphate radicals are permanently changed, the properties of the oligonucleotides often change drastically. For example, phosphorothioate oligonucleotides often act in a sequence-non-specific manner.

It is therefore a further object of the invention to make available oligonucleotide analogues having specific activity and increased serum stability, which change back again into their natural phosphodiester oligonucleotides in biological systems (serum, organ, cell).

One or more internucleotide phosphate radicals in the oligonucleotides can be modified as a prodrug. It has been found that oligonucleotides having 3' and/or 5'-terminal prodrug modification are more stable even in the serum than the naturally occurring phosphodiester oligonucleotides.

The invention is not restricted to α- and β-D- or L-ribofuranosides, α- and β-D- or L-desoxyribofuranosides and corresponding carbocyclic five-membered ring analogues, but also applies to oligonucleotide analogues which are built up from other sugar units, for example ring-expanded and ring-contracted sugars, acyclic, ring-bridged or suitable sugar derivatives of a different kind. The invention is furthermore not restricted to the derivatives of the phosphate radical shown by way of example in formula I, but also relates to the known dephospho derivatives.

The oligonucleotides can thus be modified from the natural structure in a variety of ways. Such modifications, which are introduced by methods known per se, are, for example:



a) Modifications of the phosphate bridge
The following may be mentioned by way of example: phosphorothioates, phosphorodithioates, methylphosphonates, phosphoramidates, boranophosphates, phosphate methyl esters, phosphate ethyl esters, phenylphosphonates. Preferred modifications of the phosphate bridge are phosphorothioates, phosphorodithioates and methylphosphonates.

b) Replacement of the phosphate bridge
The following may be mentioned by way of example: replacement by formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethylhydrazo, dimethylene sulphone, silyl groups. The one preferred is the replacement by formacetals and 3'-thioformacetals.

c) Modifications of the sugar
The following may be mentioned by way of example: α-anomeric sugars, 2'-O-methylribose, 2'-O-butylribose, 2'-O-allylribose, 2'-fluoro-2'-deoxyribose, 2'-amino-2'-deoxyribose, α-arabinofuranose, carbocyclic sugar analogues. The preferred modification is that by 2'-O-methylribose and 2'-O-n-butylribose.

d) Modifications of the bases which do not change the specificity of the Watson-Crick base pairing
The following may be mentioned by way of example: 5-propynyl-2'-deoxyuridine, 5-propynyl-2'-deoxycytidine, 5-hexynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxycytidine, 5-fluoro-2'-deoxycytidine, 5-fluoro-2'-deoxyuridine, 5-hydroxymethyl-2'-deoxyuridine, 5-methyl-2'-deoxycytidine, 5-bromo-2'-deoxycytidine. Preferred modifications are 5-propynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxycytidine and 5-propynyl-2'-deoxycytidine.

e) 3'-3'- and 5'-5'-inversions [e.g. M. Koga et al., J. Org. Chem. 56 (1991) 3757]

f) 5'- and 3'-phosphates, and also 5'- and 3'-thiophosphates.

Exemplary groups which favour intracellular absorption are various lipophilic radicals such as $-O-(CH_2)_x-CH_3$, in which x is an integer from 6 to 18, $-O-(CH_2)_n-CH=CH-(CH_2)_m-CH_3$, in which n and m independently of one another are an integer from 6 to 12, $-O-(CH_2CH_2O)_4-(CH_2)_9-CH_3$, $-O-(CH_2CH_2O)_8-(CH_2)_{13}-CH_3$ and $-O-(CH_2CH_2O)_7-(CH_2)_{15}-CH_3$, but also steroid radicals such as cholesteryl or vitamin radicals such as vitamin E, vitamin A or vitamin D and other conjugates which utilize natural carrier systems, such as bile acid, folic acid, 2-(N-alkyl, N-alkoxy) aminoanthraquinone and conjugates of the mannose and peptides of the corresponding receptors which lead to receptor-mediated endocytosis of the oligonucleotides, such as EGF (epidermal growth factor), bradykinin and PDGF (platelet derived growth factor).

The synthesis of the oligonucleotide is carried out according to processes known to the person skilled in the art such as the triester method, the H-phosphonate method or phosphoramidite method, preferably by standard phosphoramidite chemistry according to Caruthers (M.D. Matteucci and M.H. Caruthers, J. Am. Chem. Soc. 103, 3185 (1981)).

It has further been found that compounds of the formula I in which W is formula II and R is formula II', depending on the base sequence of the DNA moiety, inhibit the expression of specific genes, for example of enzymes, receptors or growth factors, in cell culture and in selected examples in animal models.

Very generally, the present invention extends to the use of compounds of the formula I as therapeutically active constituents of a pharmaceutical. Therapeutically active oligonucleotide derivatives are understood as in general meaning anti-sense oligonucleotides, triple helix-forming

oligonucleotides, aptamers or ribozymes, in particular anti-sense oligonucleotides.

The pharmaceuticals of the present invention can be used, for example, for the treatment of illnesses which are caused by viruses, for example by HIV, HSV-1, HSV-2, influenza, VSV, hepatitis B or papilloma viruses.

Anti-sense oligonucleotide derivatives according to the invention, which are active against such targets, have, for example, the following base sequence:

a) against HIV, e.g.

5'-A C A C C C A A T T C T G A A A A T G G-3' or
(I)

5'-A G G T C C C T G T T C G G G C G C C A-3' or
(II)

5'-G T C G A C A C C C A A T T C T G A A A A T G G A T A A-3' or
(III)

5'-G C T A T G T C G A C A C C C A A T T C T G A A A-3' or
(IV)

5'-T C G T C G C T G T C T C C G C T T C T T C T T C C T G C C A or
(VI)

b) against HSV-1, e.g.
5'-G C G G G G C T C C A T G G G G G T C G-3'
(VII)

The pharmaceuticals of the present invention are also suitable, for example, for the treatment of cancer. For example, in this case oligonucleotide sequences can be used which are directed against targets which are responsible for carcinogenesis or cancer growth. Such targets are, for example:

1) nuclear oncoproteins such as c-myc, N-myc, c-myb, c-fos, c-fos/jun, PCNA, p120

2) cytoplasmic/membrane-associated oncoproteins such as EJ-ras c-Ha-ras, N-ras, rrg, bcl-2, cdc-2, c-raf-1, c-mos, c-src, c-abl

3) cellular receptors such as EGF receptor, c-erbA, retinoid receptors, protein kinase regulatory subunits, c-fms

4) cytokines, growth factors, extracellular matrix such as, for example, CSF-1, IL-6, IL-1a, IL-1b, IL-2, IL-4, bFGF, myeloblastin, fibronectin,

Anti-sense oligonucleotides of the formula I according to the invention which are active against such targets have, for example, the following base sequence:

a) against c-Ha-ras, e.g.

5'CAGCTGCAACCCAGC-3'
(VIII)

c) c-myc, e.g.

5'-G G C T G C T G G A G C G G G G C A C A C-3'
(IX)

5.-A A C G T T G A G G G G C A T-3'
(X)

d) c-myb, e.g.

5'-G T G C C G G G G T C T T C G G G C-3'
(XI)

e) c-fos, e.g.

5'-G G A G A A C A T C A T G G T C G A A A G-3'
(XII)

5'-C C C G A G A A C A T C A T G G T C G A A G-3'
(XIII)

5'-G G G G A A A G C C C G G C A A G G G G-3'
(XIV)

f) p120, e.g.

5'-C A C C C G C C T T G G C C T C C C A C-3'
(XV)

g) EGF receptor, e.g.

5'-G G G A C T C C G G C G C A G C G C-3'
(XVI)

5'-G G C A A A C T T T C T T T T C C T C C-3'
(XVII)

h) p53 tumour suppressor, e.g.

5'-G G G A A G G A G G A G G A T G A G G-3'
(XVIII)

5'-G G C A G T C A T C C A G C T T C G G A G-3'r
(XIX)

The pharmaceuticals of the present invention are further suitable, for example, for the treatment of illnesses which are affected by integrins or cell-cell adhesion receptors, for example by VLA-4, VLA-2, ICAM, VCAM or ELAM.

Anti-sense oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence:

a) VLA-4, e.g.

5'-G C A G T A A G C A T C C A T A T C-3' or
(XX)

b) ICAM, e.g.

5'- C C C C C A C C A C T T C C C C T C T C-3'
(XXI)

5'-C T C C C C C A C C A C T T C C C C T C-3'
(XXII)
5'-G C T G G G A G C C A T A G C G A G G-3'
(XXIII)

c) ELAM-1, e.g.

5'-A C T G C T G C C T C T T G T C T C A G G-3'
(XXIV)

5'-C A A T C A A T G A C T T C A A G A G T T C-3'
(XXV)

The pharmaceuticals of the present invention are also suitable, for example, for the prevention of restenosis. For example, in this case oligonucleotide sequences can be used which are directed against targets which are responsible for proliferation or migration. Such targets are, for example:

1) nuclear transactivator proteins and cyclins such as c-myc, c-myb, c-fos, c-fos/jun, cyclins and cdc2-kinase

2)mitogenic or growth factors such as PDGF, bFGF, EGF, HB-EGF and TGF-β.

3) Cellular receptors such as bFGF receptor, EGF receptor and PDGF receptor.

Anti-sense oligonucleotides of the formula I according to the invention which are active against such targets have, for example, the following base sequence:

a) c-myb
5'-G T G T C G G G G T C T C C G G G C-3'
(XXVI)

b) c-myc
5'-C A C G T T G A G G G G C A T-3'
(XXVII)

c) cdc2-kinase
5'-G T C T T C C A T A G T T A C T C A-3'
(XXVIII)

d) PCNA (proliferating cell nuclear antigen of rat)
5'-G A T C A G G C G T G C C T C A A A-3'
(XXIX)

Suitable administration forms for compounds of the formula I in which W and R, together with the phosphonate radical carrying them, form an oligonucleotide are topical applications, local applications such as with the aid of a catheter or alternatively injections. For injection, the anti-sense oligonucleotide derivatives are formulated in a liquid solution, preferably in a physiologically acceptable buffer, such as Hank's solution or Ringer's solution. The anti-sense oligonucleotides, however, can also be formulated in solid form and dissolved or suspended before use. The doses preferred for systemic administration are about 0.01 mg/kg to about 50 mg/kg of body weight per day.

The pharmaceuticals can also be used, for example, in the form of pharmaceutical preparations which are administered orally, e.g. in the form of tablets, coated tablets, hard or soft gelatin capsules, solutions, emulsions or suspensions. The inclusion of the pharmaceuticals in

AUSTRALIAN PATENT OFFICE

liposomes which optionally contain further components such as proteins is an administration form which is also suitable. They can also be administered rectally, e.g. in the form of suppositories or parenterally, e.g. in the form of injection solutions. For the production of pharmaceutical preparations, these compounds can be processed in therapeutically inert organic and inorganic excipients. Examples of such excipients for tablets, coated tablets and hard gelatin capsules are lactose, maize starch or derivatives thereof, tallow and stearic acid or salts thereof. Suitable excipients for the preparation of solutions are water, polyols, sucrose, invert sugar and glucose. Suitable excipients for injection solutions are water, alcohols, polyols, glycerol and vegetable oils. Suitable excipients for suppositories are vegetable and hardened oils, waxes, fats and semi-liquid polyols. The pharmaceutical preparations can also contain preservatives, solvents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colourants, flavourings, salts for changing the osmotic pressure, buffers, coating agents, antioxidants, and also, if appropriate, other therapeutic active compounds.

In-vitro anti HIV tests of the dinucleoside α-hydroxymethylarylphosphonates 1-3

In-vitro HIV tests were carried out with the dinucleoside α-hydroxymethylarylphosphonates 1-3. As a test system human T lymphocytes (CEM/O) were used. The compounds were additionally tested in a thymidine kinase-deficient T-lymphocyte strain (CEM/TK^-). The CEM/O cells were infected both with HIV-1 and with HIV-2. Before the tests, it was ensured that the compounds to be tested were free of free nucleoside (max. 0.5% HPLC). The results of the test assays are listed in Table 1.

As can be seen from Table 1, all compounds exhibit high activity both against HIV-1 and HIV-2 replication.

In contrast to the prodrug forms already described in the literature, the compounds of the formula I according to the invention exhibited no cytotoxic action.

AUSTRALIAN PATENT OFFICE

Table 1: Results of the anti-HIV in vitro test assays of 1-3, 11-13, 4-6 and 28-30 against HIV-1 and HIV-2 in human T lyphocytes (CEM/O and CEM/TK$^-$)

Table 1: Synthesized α-hydroxymethylarylphosphonic acid diesters 1-3



Nucleoside analogues

Nucleoside analogues

1: Nucleoside = 2',3'-dideoxythymidine (ddT); 2: Nucleoside = 2',3'-dideoxy-2',3'-didehydrothymidine (d4T); 3: Nucleoside = 3'-Deoxy-3'-azodothymidine (AZT)

1-3	X'	Y	Z
a	NMe_2	H	H
b	OCH_3	H	H
c	CH_3	H	H
d	H	H	H
e	Cl	H	H
f	H	Cl	Cl
g	CN	H	H
h	NO_2	H	H
i	H	NO_2	H

AUSTRALIAN PATENT OFFICE

1-3	X'	Y	Z
j	NO_2	NO_2	H
k	H	NO_2	NO_2

		Antiviral activity EC_{50}[a] (µg/ml) CEM/O			
Compound	Substituent	HIV-1	HIV-2	CEM/TK$^-$ HIB-2	Toxicity CC_{50}[b] (µg/ml)
1a	NMe_2	3.25 ± 1.06	7.0 ± 4.24	> 100	> 100
1b	OCH_3	0.5 ± 0.0	0.55 ± 0.07	> 20	> 20
1c	CH_3	3.25 ± 1.06	10.0 ± 0.0	> 100	> 100
1d	H	2.93 ± 1.85	13.3 ± 2.9	> 100	> 100
1e	Cl	4.0 ± 0.0	4.0 ± 0.0	> 100	> 100
1f	2,6-di-Cl	1.4 ± 0.85	2.0 ± 0.0	> 20	> 20

		Antiviral activity EC_{50}[a] (μg/ml) CEM/O			
Compound	Substituent	HIV-1	HIV-2	CEM/TK⁻ HIB-2	Toxicity CC_{50}[b] (μg/ml)
1g	CN	3.93 ± 3.10	7.7 ± 4.6	> 100	> 100
1h	NO_2	2.25 ± 0.35	3.0 ± 1.41	> 100	> 100
1j	2,4-di-NO_2	2.0 ± 0.0	3.50 ± 0.71	> 100	> 100
2b	OCH_3	0.10 ± 0.065	0.12 ± 0.06	> 100	> 20
2c	CH_3	0.12 ± 0.064	0.33 ± 0.24	> 100	> 20
2d	H	0.16 ± 0.0	0.19 ± 0.19	> 100	> 100
2e	Cl	0.10 ± 0.05	0.12 ± 0.06	> 100	> 100
2f	2,6-di-Cl	0.056 ± 0.034	0.12 ± 0.06	> 20	> 100
2g	CN	0.091 ± 0.065	0.33 ± 0.24	> 100	> 100
2h	NO_2	0.066 ± 0.048	0.12 ± 0.06	> 100	> 100
2j	2,4-di-NO_2	0.16 ± 0.0	0.33 ± 0.24	> 100	> 100

The compounds according to the invention have higher partition coefficients in an octanol/water mixture than the nucleoside analogues on which they are based. They are therefore better passively transportable through biomembranes.

The invention is intended to be illustrated in more detail by the following working examples and by the contents of the Patent Claims.

Examples

1. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-methylphenyl)methylphosphonate:
904 mg (4.0 mmol) of 2',3'-dideoxythymidine were dried in a high vacuum and then dissolved in 60 ml of dry acetonitrile. This solution were treated with 774 mg (6.0 mmol; 1.07 ml) of diisopropylethylamine and cooled to 0°C in an ice bath. 404 mg (2.0 mmol) of diisopropylamine dichlorophosphine were then added in portions in the course of 15 minutes. After addition was complete, the mixture was stirred for 15 minutes while warming to room temperature. At room temperature, 254 mg (4.0 mmol) of tetrazole and 80 ml of water were added. After stirring for 30 minutes, the solvent was condensed out on the high-vacuum unit. The residue was purified on silica gel with the aid of a gradient of ethyl acetate/methanol (0% to 30% methanol) on the Chromatotron. The product was isolated as a colourless solid (797 mg [1.6 mmol]; 80% yield). 797 mg (1.6 mmol) of 2',3'-ddT-H-phosphonate diester were dissolved in 40 ml of dry tetrahydrofuran and treated with 518 mg (4.8 mmol) of 4-methylbenzaldehyde. 20 ml of dry, previously distilled triethylamine was added to this solution with stirring. After 4 hours at room temperature, the starting material had reacted. Final checking was carried out with the aid of reversed-phase HPLC chromatography. The reaction mixture was neutralised by addition of 20 ml of acetic acid and concentrated to dryness on a rotary evaporator. The

residue was purified on the Chromatotron with the aid of a gradient of methylene chloride/methanol (0% to 15% methanol). The product was isolated as a colourless solid after lyophilization (921 mg [1.52 mmol]; 95% yield). For the purification of the compound for the in-vitro anti-HIV tests, a semi-preparative HPLC purification was additionally carried out with an isocratic eluent mixture (30% methanol in acetonitrile).

2. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-dimethylaminophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-dimethylaminobenzaldehyde was employed here. (Yield 90%).

3. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-methoxyphenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-methoxybenzaldehyde was employed here (yield 87%).

4. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(phenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde benzaldehyde was employed here (yield 93%).

5. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-chlorophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-chlorobenzaldehyde was employed here (yield 90%).

6. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-cyanophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-cyanobenzaldehyde was employed here (yield 86%).

7. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-nitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-nitrobenzaldehyde was employed here (yield 85%).

8. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(2-nitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 2-nitrobenzaldehyde was employed here (yield 87%).

9. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(2,4-dinitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 2,4-dinitroenzaldehyde was employed here (yield 85%).

10. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(9-fluorenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 9-fluorenone was employed here (yield 91%).

11. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(4-pyridyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 4-pyridylaldehyde was employed here (yield 82%).

12. Preparation of bis(5'-O-2',3'-dideoxythymidine) hydroxy(2,6-dichlorophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 4-methylbenzaldehyde 2,4-dichlorobenzaldehyde was employed here (yield 96%).

13. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-methoxyphenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-methoxybenzaldehyde was employed (yield 80%).

14. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-methylphenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was

employed here (yield 83%).

15. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(phenyl)methylphosphonate: Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde benzaldehyde was employed (yield 87%).

16. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-chlorophenyl)methylphosphonate: Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-chlorobenzaldehyde was employed (yield 86%).

17. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-cyanophenyl)methylphosphonate: Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-cyanobenzaldehyde was employed (yield 86%).

18. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-nitrophenyl)methylphosphonate: Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-nitrobenzaldehyde was employed (yield 81%).

19. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(2-nitrophenyl)methylphosphonate: Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2-nitrobenzaldehyde was employed (yield 86%).

20. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(2,4-dinitrophenyl)methyl-

phosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,4-dinitrobenzaldehyde was employed (yield 80%).

21. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(4-pyridyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-pyridylaldehyde was employed (yield 80%).

22. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy(2,6-dichlorophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,6-dichlorobenzaldehyde was employed (yield 87%).

23. Preparation of bis(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxyheptylmethylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde octanal was employed (yield 75%).

24. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxy(4-nitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-nitrobenzaldehyde was employed (yield 96%).

25. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxy(2-nitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was

employed here and instead of 4-methylbenzaldehyde 2-nitrobenzaldehyde was employed (yield 92%).

26. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxy(2,6-dinitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,6-dinitrobenzaldehyde was employed (yield 88%).

27. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxy(2,4-dinitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,4-dinitrobenzaldehyde was employed (yield 90%).

28. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxy(4-pyridyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-pyridylaldehyde was employed (yield 96%).

29. Preparation of bis(5'-O-2',3'-dideoxy-3'-azidothymidine) hydroxyheptylmethylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde octanal was employed (yield 96%).

30. Preparation of (5'-O-2',3'-dideoxy-3'-azidothymidine)-(5'-O-2',3'-dideoxythymidine) hydroxy(2,6-dinitrophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, ddT/AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,6-

nitrobenzaldehyde was employed (yield 88%).

31. Preparation of (5'-O-2',3'-dideoxy-3'-azidothymidine)-(5'-O-2',3'-dideoxy-2,3-didehydrothymidine) hydroxy (4-nitrophenyl) methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T/AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-nitrobenzaldehyde was employed (yield 96%).

32. Preparation of (5'-O-2',3'-dideoxy-3'-azidothymidine)-(5'-O-2',3'-dideoxy-2,3-didehydrothymidine) hydroxy (2,6-dinitrophenyl) methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T/AZT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2,6-dinitrobenzaldehyde was employed (yield 87%).

40. Preparation of (5'-O-2',3'-dideoxythymidine)-(5'-O-2',3'-dideoxy-2,3-didehydrothymidine) hydroxy (2-nitrophenyl) methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T/ddT-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2-nitrobenzaldehyde was employed (yield 91%).

41. Preparation of (5'-O-thymidine)-(5'-O-2',3'-dideoxy-2',3'-didehydrothymidine) hydroxy (2-nitrophenyl) methyl-phosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, d4T/T-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 2-nitrobenzaldehyde was employed (yield 85%).

42. Preparation of bis (5'-O-3'-O)-levulinylthymidine hydroxy (4-chlorophenyl) methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, 3'-levulinylthymidine-H-phosphonate diester was employed here and instead of

4-methylbenzaldehyde 4-chlorobenzaldehyde was employed (yield 93%).

43. Preparation of bis(5'-O-3'-O-t-butyldimethylsilyl-thymidine)hydroxy(4-chlorophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, 3'-levulinylthymidine-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-chlorobenzaldehyde was employed (yield 85%).

44. Preparation of bis(5'-O-3'-O-acetylthymidine)hydroxy-(4-chlorophenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, 3'-acetylthymidine-H-phosphonate diester was employed here and instead of 4-methylbenzaldehyde 4-chlorobenzaldehyde was employed (yield 75%).

45. Preparation of bis(5'-O-3'-O-acetylthymidine)hydroxy-(4-methoxyphenyl)methylphosphonate:
Analogous procedure as in 1. Instead of 2',3'-ddT-H-phosphonate diester, 3'-acetylthymidine-H-phosphonate diester was employed here and instead of 4-methyl-benzaldehyde 4-methoxybenzaldehyde was employed (yield 70%).

46. Preparation of bis(5'-O-thymidine) hydroxy(4-chloro-phenyl)methylphosphonate: preparation was carried out from the 3'-O-levulinyl-protected derivative described in 5a) according to standard conditions with the aid of 5 equivalents of hydrazine hydrate in pyridine/acetic acid 4:1 in the course of 15 minutes at room temperature.

47. Preparation of di(5'-O-2',3'-dideoxy-2',3'-didehydro-thymidine) phosphite:
Analogous procedure as in 1. Instead of 2',3'-dide-oxythymidine 2',3'-dideoxy-2',3'-didehydrothymidine was employed (yield 75%).

48. Preparation of di(5'-O-2',3'-dideoxy-3'-azidothymidine) phosphite:
Analogous procedure as in 1. Instead of 2',3'-dideoxythymidine, 2',3'-dideoxy-3'-azidothymidine was employed (yield 85%).

49. Preparation of di(5'-O-3'-levulinylthymidine) phosphite:
Analogous procedure as in 1. Instead of 2',3'-dideoxythymidine, 3'-levulinylthymidine was employed (yield 65%).

50. Preparation of di(5'-O-3'-t-butyldimethylsilylthymidine) phosphite:
Analogous procedure as in 1. Instead of 2',3'-dideoxythymidine, 3'-t-butyldimethylsilylthymidine was employed (yield 65%).

51. Preparation of di(5'-O-3'-acetylthymidine) phosphite:
Analogous procedure as in 1. Instead of 2',3'-dideoxythymidine, 3'-acetylthymidine was employed (yield 86%).

The reactions with the strongly acceptor-substituted benzaldehydes (4-nitro-, 2-nitro-, and 2.4-dinitrobenzaldehyde) could also be carried out using the chiral quinine as a base. The reactions with the donor-substituted benzaldehydes (4-dimethylamino-, 4-methoxy-, 4-methyl- and benzaldehyde) were also carried out in pure triethylamine with heating alternatively to the experiments described above.

52. Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'5')-thymidine-3'-((O-triethylsiloxy)-2-nitrobenzyl) phosphonate (TES-protected hydroxy-3'-OH phosphonate dimer D):

a) Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'5')-3'-O-levulinylthymidine-3'-H-phosphonate:

AUSTRALIAN PATENT OFFICE

(H-phosphonate dimer A)

1.9 g (2.7 mmol; 1.1 eq.) of 5'-O-(4,4'-dimethoxytrityl)-thymidylyl-3'-H-phosphonate were dried in a high vacuum and dissolved in 30 ml of dry pyridine. 828 mg (2.4 mmol; 1.0 eq.) of predried 3'-O-levuinylthymidine were added to this solution. 899 ml of freshly distilled pivaloyl chloride were then added dropwise and stirring was continued at room temperature. After 8 min, the mixture was diluted with 150 ml of methylene chloride and extracted in a separating funnel using 150 ml of 5% strength sodium hydrogen carbonate solution. After extraction a further two times using 150 ml of methylene chloride each time, the extract was dried over sodium sulphate, filtered off from the drying agent and concentrated to dryness on a rotary evaporator. The crude product was purified by means of flash chromatography. The gradient of the eluent ethyl acetate/methanol (+ addition of 0.1% acetic acid) was increased from 0% to 5% methanol.

The product was isolated as a yellow solid (1.972 g; 2.12 mmol; 78%).

b) Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'5')-3'-O-levulinylthymidine-3'-((-hydroxy)-2-nitrobenzyl)phosphonate:

(α-hydroxyphosphonate dimer B)

1.5 g (1.6 mmol; 1 eq.) of the H-phosphonate dimer A were dissolved in predried form in 20 ml of dry methylene chloride. This solution was treated with 725 mg (4.8 mmol; 3 eq.) of predried 2-nitrobenzaldehyde and then with 40 ml of triethylamine. After stirring at room temperature for 8 hours, it was neutralized with acetic acid and the solution was purified directly by means of flash chromatography. The gradient of the eluent methylene chloride/methanol (+ addition of 0.1% acetic acid) was increased from 0% to 5% methanol.

The product is a colourless solid (1.374g; 1.27 mmol; 79%).

AUSTRALIAN PATENT OFFICE

c) Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'5')-3'-O-levulinylthymidine-3'-((-O-triethylsiloxy)-2-nitrobenzyl)phosphonate:

(TES-protected hydroxyphosphonate dimer C)

1.1 g (1.01 mmol; 1 eq.) of -hydroxyphosphonate dimer B were dissolved in predried form in 20 ml of dry pyridine. 914 mg (6.07 mmol; 1.02 ml; 6 eq.) of triethylsilyl chloride were added dropwise to this solution and it was stirred at room temperature. After stirring for seven hours, it was concentrated to dryness on a rotary evaporator.

The crude product was purified by means of flash chromatography. The gradient of the eluent ethyl acetate/methanol was increased from 0% to 4% methanol.

The product is a pale yellow solid (1.13 g; 0.95 mmol; 93%).

d) Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'5')-thymidine-3'-((- O-triethylsiloxy)-2-nitrobenzyl)-phosphonate (D):

1.1 g (0.92 mmol) of TES-protected hydroxyphosphonate dimer C were dissolved in 10 ml of pyridine and treated with 10 ml of a solution of 3 ml of hydrazine hydrate (24% in water), 6.92 ml of pyridine and 4.61 ml of acetic acid. After stirring at room temperature for three minutes, the solution was cooled to 0°C and diluted with 100 ml of water and 100 ml of ethyl acetate. After separating the phases in a separating funnel, the organic phase was washed once with 25 ml of a 5% strength sodium hydrogen carbonate solution and then dried over sodium sulphate. After separating off the drying agent, it was concentrated to dryness on a rotary evaporator. The crude product was purified by means of flash chromatography. The gradient of the eluent methylene chloride/methanol was increased from 0% to 7% methanol.

The product was isolated as a pale yellow solid (858 mg; 0.78 mmol; 85%).

53. Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-

(3'5')thymidine-3'-O-(β-cyanoethyldiisopropylaminophosphoramidite)-((O-triethylsiloxy)-2-nitrobenzyl)phosphonate

(TES-protected hydroxy-3'-phosphoramidite-phosphonate dimer E)

230 mg (0.21 mmol; 1 eq.) of TES-protected hydroxy-3'-OH phosphonate dimer D were dissolved in predried form in 15 ml of dry methylene chloride, treated with stirring with 177 ml (1.05 mmol; 135 mg; 5 eq) of diisopropylethylamine and then with 70 ml (0.31 mmol; 74.2 mg; 1.5 eq) of β-cyanoethyldiisopropylchlorophosphine. The mixture was stirred at room temperature for 5 hours, 20 ml of ethyl acetate was added and it was concentrated to dryness on a rotary evaporator. It was then extracted twice with 20 ml of 2% strength sodium hydrogen carbonate solution each time followed by saturated sodium chloride solution. The organic phase was dried over sodium sulphate. After filtration, the residue was concentrated to dryness on a rotary evaporator.

The crude product was purified by means of flash chromatography. As an eluent, methylene chloride/acetonitrile 1:1 (+ addition of 1% triethylamine) was used.

The product is a pale yellow solid (123 mg; 0.095 mmol; 45%).

54. Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'→5')thymidine-3'-O-succinyl((-O-triethylsiloxy)-2-nitrobenzyl)phosphonate

(TES-protected hydroxy-3'-succinylphosphonate dimer F)

200 mg (0.18 mmol; 1.4 eq) of TES-protected hydroxy-3'-OH-phosphonate dimer D were dissolved in predried form in 2 ml of dry pyridine. 24.4 mg (0.2 mmol) of 4-dimethylaminopyridine and 20.0 mg (0.2 mmol) of succinic anhydride were then added successively and the mixture was allowed to react at room temperature for 4 hours with stirring. 45 ml of water were added and, after stirring for 10 minutes, the mixture was concentrated to dryness on a rotary evaporator. The residue was taken up in 15 ml

of methylene chloride and extracted once with 8 ml of cold 10% strength citric acid and twice with 8 ml of cold water each time. The organic phase was then dried over sodium sulphate. After filtration, it was concentrated to dryness on a rotary evaporator. The crude product was taken up in 3 ml of methylene chloride and added dropwise to 25 ml of ice-cold n-hexane. The product was deposited as a colourless precipitate. To complete the precipitation, the mother liquor was stored at -20°C for a few hours, then the solid was filtered off and dried. The product is a colourless solid (167 mg; 0.14 mmol; 78%).

55. Preparation of 5'-O-(4,4'-dimethoxytrityl)thymidylyl-(3'→5')thymidine-3'-O-succinyl-CPG((α-O-triethylsiloxy)-2-nitrobenzyl)phosphonate

(CPG-bound TES-protected hydroxy-3'-succinylphosphonate dimer G)

50 mg (0.042 mmol; 1.5 eq.) of TES-protected hydroxy-3'-succinylphosphonate dimer F were dissolved in 1.5 ml of dry dimethylformamide in a Pierce flask and treated with 13.41 mg (0.042 mmol; 1.5 eq.) of O-benzotriazol-1-yl-N,N,N',N',-tetramethyluronium tetrafluoroborate (TBTU) and 4.2 ml (0.033 mmol; 3.84 mg; 1.2 eq.) of N-ethylmorpholine. 370 mg of CPG support were then added and the mixture was shaken at room temperature for a further 4 hours. It was transferred to a frit, washed with methanol and methylene chloride, transferred to the Pierce flask again and treated with 1.5 ml of capping reagent. It was shaken for a further hour, again transferred to a frit, filtered off, washed with methanol, methylene chloride, tetrahydrofuran and diethyl ether and dried at 40°C in an oil pump vacuum.
Loading of the support: 47.12 mmol/g

56. Preparation of an oligonucleotide of the formula

TTTTTTTTT(pp)T

(pp is an α-hydroxy(o-nitrophenyl)methylphosphonate bridge)

The CPG support from Example 55, which contains 1 μmol of

the dinucleotide bonded via the 3'-end, is successively treated with the following reagents:

1. Acetonitrile abs.
2. 2 % dichloroacetic acid in dichloromethane
3. Acetonitrile abs.
4. 10 µmol of β-cyanoethyl 5'-O-dimethoxytrityl-thymidine-3'-phosphatediisopropylamidite and 40 µmol of tetrazole in acetonitrile abs.
5. Acetonitrile
6. 20% acetic anhydride in THF containing 40% lutidine and 10% dimethylaminopyridine
7. Acetonitrile
8. Iodine (1.3 gr in THF/water/pyridine; 70:20:5=v:v:v)

Steps 1 to 8, subsequently called a reaction cycle, are repeated 7 times to synthesize the decathymidylate derivative. After synthesis has been concluded, the dimethoxytrityl group is removed as described in steps 1 to 3. By treatment with ammonia, the oligonucleotide is cleaved from the support and at the same time the β-cyanoethyl groups are eliminated. The silyl protective group is removed by treatment with 80% strength acetic acid. The decathymidylate derivative crude product obtained, which at the 3'-end contains a (-hydroxy-o-nitrophenylmethylphosphonate) internucleotide bond, is purified by polyacrylamide gel electrophoresis or HPLC.

57. Preparation of an oligonucleotide of the formula

T(pp)TTTTTTTTT

Commercially obtainable CPG support, which contains 1 µmol of the 5'-O-dimethoxytritylthymidine bonded via the 3'-end, is treated successively with the following reagents:

1. Acetonitrile abs.
2. 2 % dichloroacetic acid in dichloromethane
3. Acetonitrile abs.

4. 10 µmol of β-cyanoethyl 5'-O-dimethoxytrityl-thymidine-3'-phosphite diisopropylamidite and 40 µmol of tetrazole in acetonitrile abs.
5. Acetonitrile
6. 20% acetic anhydride in THF containing 40% lutidine and 10% dimethylaminopyridine
7. Acetonitrile
8. Iodine (1.3 gr in THF/water/pyridine; 70:20:5=v:v:v)

Steps 1 to 8, subsequently called a reaction cycle, are repeated 7 times to synthesize the decathymidylate derivative. In the last cycle, instead of the monomer in step 4 the corresponding dinucleotide, which was prepared as in Example 53, is employed. After synthesis has been concluded, the dimethoxytrityl group is removed as described in steps 1 to 3. By treatment with ammonia, the oligonucleotide is cleaved from the support and at the same time the β-cyanoethyl groups are eliminated. The silyl protective group is removed by treatment with 80% strength acetic acid. The decathymidylate derivative crude product obtained, which at the 5'-end contains a (-hydroxy-o-nitrophenylmethylphosphonate) internucleotide bond, is purified by polyacrylamide gel electrophoresis or HPLC.

58. Preparation of an oligonucleotide of the formula:

T(pp)TTTTTTTT(pp)T

(pp is in each case an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge)

Synthesis is carried out in an analogous manner to that described in Example 56 starting from T(pp)T-CPG support from Example 55, which contains 1 µmol of the dinucleotide bonded via the 3'-end. In the last cycle, instead of the monomer in step 4, the corresponding dinucleotide which was prepared as in Example 53, is employed. After synthesis has been concluded, the dimethoxytrityl group is removed as described in steps 1 to 3. By treatment

with ammonia, the oligonucleotide is cleaved from the support and at the same time the β-cyanoethyl groups are eliminated. The silyl protective group is removed by treatment with 80% strength acetic acid. The decathymidylate derivative crude product obtained, which at the 3'-end and at the 5'-end in each case contains a (-hydroxy-o-nitrophenylmethylphosphonate)internucleotide bond, is purified by polyacrylamide gel electrophoresis or HPLC.

59. Preparation of GCAGGAGGATGCTGAGGAGG(pp)C (HSV target)
Preparation is carried out analogously to that described in Example 56, starting from corresponding G(pp)C-CPG support instead of T(pp)T-CPG. In the condensation reactions, in step 4 in each case the monomer building block of deoxyadenosine, deoxyguanosine or deoxycytidine corresponding to the sequence are employed. Those commercially obtainable building blocks which have rapidly removable protective groups (®Expedite Fast Deprotecting Amidites; Millipore, Eschborn) are preferred.

60. Preparation of G(pp)CAGGAGGATGCTGAGGAGG(pp)C
Preparation is carried out in an analogous manner to that described in Example 5, the corresponding G(pp)C phosphoramidite being employed in the last condensation step instead of the T(p)T phosphoramidite.

61. Preparation of G(pp)CAGGAGGATG(pp)CTGAGGAGG(pp)C
Preparation is carried out in an analogous manner to that described in Example 5, the corresponding G(pp)C phosphoramidite being employed in each case in the eighth and in the last condensation step.

62. Preparation of G(pp)CGGGGCTCCATGGGGGTC(pp)G
Preparation is carried out in an analogous manner to that described in Example 60, starting from corresponding C(pp)G-CPG support instead of G(pp)C-CPG.

63. Preparation of C(pp)GAGAACATCATGGTC(pp)G(c-fos Target)

Preparation is carried out in an analogous manner to that described in Example 62, the corresponding C(pp)G phosphoramidite being employed in the last cycle.

64. Characterization of the oligonucleotides

Characterization is carried out with the aid of HPLC, polyacrylamide gel electrophoresis (PAGE) and negative ion electrospray mass spectrometry (ES-MS$^-$). The products are purified as described above and afterwards exhibit a homogeneous band in the PAGE (20% acrylamide, 2% bisacrylamide and 7 M urea). HPLC is carried out on reversed phase columns RP-18 from Merck or on a PA-100 column from Dionex.

For the ES-MS$^-$, the oligonucleotides are converted into the ammonium salts by ammonium acetate precipitation or other salt exchange. The sample application is carried out from a solution in acetonitrile/water (1:1) containing 5 OD_{260}/ml of oligomer. The accuracy of the method is about ± 1.5 Daltons.

65. Determination of the stability and cell absorption after radioactive labelling

Radioactive labelling:

A generally applicable labelling with ^{35}S consists in carrying out at least one oxidation in the DNA synthesis cycle (step 20 in Example 11) using elemental ^{35}sulphur in the synthesis of the oligonucleotide. Oligonucleotides which have a free 5'-hydroxy group can be labelled with ^{32}P or ^{35}S by methods which are known per se with the aid of the polynucleotide kinase. Oligonucleotides which carry a free 3'-hydroxy group can be labelled in a known manner with 3'-terminal transferase. As an example, the 5'-labelling of the DNA moiety is presented here: the oligonucleotide having a free 5'-hydroxy group (500 pmol) is dissolved in 420 µl of water, and this solution is heated to 90°C and chilled. 50 µl of 10 x kinase buffer and 50 µl of ^{32}P gamma-ATP (6000 Ci/mmol) or ^{35S}-gamma-ATP are then added and the mixture is incubated at 37°C for

1 hour. The reaction is stopped by addition of 0.5 M EDTA solution. Desalting is carried out with the aid of an NAP® column from Pharmacia.

Investigation of the stability of the oligomer in the medium containing cells:

The supernatant 1 (10 µl) is mixed with 5 µl of 80% formamide (with XC and BB), heated at 95°C (5 minutes) and loaded onto a polyacrylamide gel (20% acrylamide, 7 M urea). After the development of the gel in an electrical field, the bands on the gel are allocated by means of autoradiography to the "stable oligomer" or the missing bands to the "degraded oligomer". Result after an incubation time of 24 hours: in comparison with the unmodified oligonucleotides, the compounds of the formula I (W equals formula II, R equals formula II') all have a greatly increased lifetime.

Determination of the cell uptake:
Vero cells are incubated in 96-well microtitre plates in DMEM, 5% FCS for 24 hours at 37°C. After the medium has been removed, the cells are washed a further two times with serum-free DMEM. The radiolabelled oligomer (10^6cpm) is diluted to a concentration of 10 µm in serum using unlabelled oligomer and the cells are incubated with it at 37°C. After 1, 7 and 24 hours, 150 µl in each case are removed (designation: "supernatant 1"). The cells in the wells of the microtitre plates are washed 7 times with 300 µl of fresh medium and the combined wash media (designation: "supernatant 2") measured in a scintillation counter. 100 µl of trypsin solution are then added, 30 seconds are waited and the supernatant is stripped off. To detach the cells from the plate, it is incubated at 37°C for 3 min. The detached cells are transferred to 1.5 ml Eppendorf vessels and centrifuged at 2000 rpm for 6 minutes ("supernatant 3"). The supernatants 1 (5µl), 2 and 3 (0.5 ml) are in each case measured separately in the scintillation counter. From this is

calculated the uptake of the oligomer in pmol per 100,000 cells, supernatant 3 being the cell-bound oligomer fraction and the sum of supernatants 1 and 2 the non-cell-bound oligomer fraction.

66. Determination of the cell uptake after fluorescence labelling:
The COS cells are allowed to grow to confluence in Dulbecco's MEM, which was supplemented with 10% FCS, in 5 cm Petri dishes. The cells are washed twice with serum-free DMEM. With the aid of a sterile needle, an area of about 1 cm^2 in the centre of the Petri dish is scraped. The DNA oligomer solution (0.1 mM) to be investigated is applied to this area. It is incubated at 37°C under a CO_2 atmosphere. After 2, 4 and 16 hours, the cells are investigated by fluorescence microscopy. For this purpose, the cells are washed four times with serum-free DMEM, covered with a glass support and assessed under the fluorescence microscope or by phase contrast.

67. Determination of the melting temperatures:
The melting temperatures are determined with the aid of an HP 8452A diode array spectrophotometer, an HP 89090A Peltier element and the HP temperature control software Rev. B5.1 (Hewlett Packard). It is measured in 0.5°C/min steps in 10 mM HEPES and 140 mM NaCl (pH 6.5) as buffer. The oligomer concentration is 0.5 to 1.5 OD_{260} per ml.

68. Testing for antiviral activity in cell culture:
The antiviral activity of the test substances against various human pathogenic herpes viruses is investigated in a cell culture test system. For the test, monkey kidney cells (Vero, 2×10^5/ml) are seeded in serum-containing Dulbecco's MEM (5% foetal calf serum FCS) in 96-well microtitre plates and incubated for 24 h at 37°C and 5% CO_2. The serum-containing medium is then aspirated and the cells are washed twice with serum-free Dulbecco's MEM (-FCS). The test substances are prediluted to a concentration of 600 µM in H_2O and stored at -18°C. For

the test, further dilution steps in Dulbecco's minimal essential medium (MEM) are carried out. 100 µl each of the individual test substance dilutions are added to the washed cells together with 100 µl of serum-free Dulbecco's MEM (-FCS). After incubation at 37°C and 5% CO_2 for 3 h, the cells are infected with herpes simplex virus type 1 (ATCC VR733, HSV-1 F-strain) or with herpes simplex virus type 2 (ATCC VR734, HSV-2 G-strain) in concentrations at which the cell lawn is completely destroyed within 3 days. In the case of HSV-1, the infection potency is 500 plaque-forming units (PFU) per well, in the case of HSV-2 350 PFU/well. The experimental batches then contain test substance in concentrations of 80 µM to 0.04 µM in MEM, supplemented by 100 U/ml of penicillin G and 100 mg/l of streptomycin. All experiments are carried out as a double determination with the exception of the controls, which are carried out eight times per plate. The experimental batches are incubated for 17 h at 37°C and 5% CO_2. The cytotoxicity of the test substances is determined after a total incubation time of 20 h by microscopic assessment of the cell cultures. The maximum tolerated dose (MTD) is designated as the highest preparation concentration which under the said experimental conditions still does not produce any microscopically detectable cell damage. After this, FCS is added to a final concentration of 4% with further incubation for 55 h at 37°C and 5% CO_2. The untreated infection controls then exhibit a complete cytopathic effect (CPE). After microscopic assessment of the cell cultures, these are then stained with Neutral Red according to the vital staining method of Finter (1966). The antiviral activity of a test substance is defined as the minimum inhibitory concentration (MIC) which is needed in order to protect 30-60% of the cells from the virus-related cytopathogenic effect. The MIC values of various oligonucleotides are in the range from 0.1 to 80 µmol/l.

69. Determination of the in vivo activity against viruses

For the testing of the compounds in vivo, 5 week-old NMRI

mice having a weight of approximately 16 to 18 grams are employed. The mice are kept under conventional conditions in groups of up to five animals and with food and water ad libitum. The mice are infected intraperitoneally with about 10 to 50 LD50 units of an HSV strain (HSV "corneae"). The compound is administered twice daily i.p. at 1, 10 or 50 mg/kg. The control animals receive a 1% strength sodium chloride solution. The survival rate of the animals is monitored over a period of 2 weeks. When the anti-sense oligonucleotides are administered there are 1 to 5 survivors, while after placebo administration all animals die.

70. Determination of the in vivo activity: Inhibition of c-Fos protein expression in the rat:
Determination is carried out as described (Sandkühler et al. (1991) in: Proceedings of the VIth World Congress on Pain, Charlton and Woolf, Editors; Elsevier, Amsterdam; page 313-318) by superfusion of the spinal cord. After laminectomy of a barbiturate anaesthetized Sprague-Dawley rat, a two-chamber container made of silicone is fashioned for containing the anti-sense oligomer. One chamber is filled with the anti-sense oligonucleotide derivative, while the other chamber is filled with the control oligomer (concentration 75 µm each). In each case, the superfusate is exchanged after one hour. After superfusion for 6 hours, c-fos expression is stimulated by heat treatment (52°C) of the hind legs. The inhibition of c-fos expression can be detected immunohistochemically on appropriate tissue section samples.

71. Preparation of 5'-O-(4,4'-dimethoxytriphenylmethyl)2-deoxythymidylyl-(3'→5')-3'-O-levulinyl-2'-deoxythymidine 3'-((α-O-tributylsiloxy)-2-nitrobenzyl)phosphonate:
TBS(tributylsiloxy)-protected hydroxyphosphonate dimer H)
1.77 g (1.636 mmol; 1 eq.) of α-hydroxyphosphonate dimer B were dissolved in predried form in 30 ml of dry pyridine. 2.62 ml (9.816 mmol; 2.306 g; 6 eq.) of chloro-

tributylsilane were added dropwise to this solution. After stirring at room temperature for 8 hours, the reaction was terminated by addition of methanol and the mixture was concentrated to dryness on a rotary evaporator.

The crude product was purified by means of flash chromatography. The gradient of the eluent ethyl acetate/methanol was increased from 0% to 2% methanol.

The product is a pale yellow solid (1.78 g; 1.39 mmol; 85%).

72. Preparation of 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxythymidylyl-(3'→5')-2'-deoxythymidine 3'-((α-O-tributylsiloxy)-2-nitrobenzyl)phosphonate:

(TBS-protected hydroxy-3'-OH-phosphonate dimer I)

1.2 g (0.94 mmol) of TBS-protected hydroxyphosphonate dimer H were dissolved in 10 ml of pyridine and treated with 10 ml of a solution of 3 ml of hydrazine hydrate (24% in water), 6.92 ml of pyridine and 4.61 ml of acetic acid. After stirring at room temperature for 3 minutes, the solution was cooled to 0°C and diluted with 100 ml of water and 100 ml of ethyl acetate. After separating the phases in a separating funnel, the organic phase was washed once with 25 ml of a 5% strength sodium hydrogen carbonate solution and then dried over sodium sulphate. The drying agent was filtered off and the filtrate was concentrated to dryness on a rotary evaporator.

The crude product was purified by means of flash chromatography. The gradient of the eluent methylene chloride/methanol was increased from 0% to 5% methanol. The product was isolated as a pale yellow solid (910 mg; 0.77 mmol; 82%).

73. Preparation of 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxythymidylyl-(3'→5')-2'-deoxythymidine 3'-O-succinyl-((α-O-tributylsiloxy)-2-nitrobenzyl)phosphonate

(TBS-protected hydroxy-3'-succinylphosphonate dimer J)

120 mg (0.10 mmol; 1 eq) of TBS-protected hydroxy-3'-OH-

phosphonate dimer I were dissolved in predried form in 1 ml of dry pyridine. 14.8 mg (0.12 mmol; 1.2 eq.) of 4-dimethylaminopyridine and 12.1 mg (0.12 mmol; 1.2 eq.) of succinic anhydride were then added successively and the mixture was stirred at room temperature for 4 hours. 40 ml of water were added and, after stirring for 10 minutes, the mixture was concentrated to dryness on a rotary evaporator. The residue was taken up in 10 ml of methylene chloride and extracted once with 5 ml of cold 10% strength citric acid and twice with 5 ml of cold water each time. The organic phase was then dried over sodium sulphate. After filtration, the filtrate was concentrated to dryness on a rotary evaporator.
The crude product was taken up in 3 ml of methylene chloride and added dropwise to 25 ml of ice-cold n-hexane. The product was deposited as a colourless precipitate. To complete the precipitation, the mother liquor was stored at -20°C for a few hours, then the solid was filtered off and dried. The product is a colourless solid (115 mg; 0.09 mmol; 90 %).

74. Preparation of 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxythymidylyl-(3'→5')-2'-deoxythymidine 3'-O-succinyl-CPG((α-O-tributylsiloxy)-2-nitrobenzyl)phosphonate; (CPG-bound TBS-protected hydroxy-3'-succinyl-phosphonate dimer K)

26.5 mg (0.021 mmol; 1.5 eq.) of TBS-protected hydroxy-3'-succinylphosphonate dimer J were dissolved in 0.7 ml of dry dimethylformamide in a Pierce flask and treated with 6.74 mg (0.021 mmol; 1.5 eq.) of O-benzotriazol-1-yl-N,N,N',N',-tetramethyluronium tetrafluoroborate (TBTU) and 2.1 ml (0.017 mmol; 1.96 mg; 1.2 eq.) of N-ethylmorpholine. 183 mg of CPG support were then added and the mixture was shaken at room temperature for a further 4 hours. It was transferred to a frit, washed with methanol and methylene chloride, transferred to the Pierce flask again and treated with 0.7 ml of capping reagent. It was shaken for a further hour, again transferred to a frit, filtered off, washed with methanol,

methylene chloride, tetrahydrofuran and diethyl ether and dried in an oil pump vacuum.
Loading of the support: 33.15 mmol/g

75. Preparation of CGTCCATGTCGGCAAACAGCT(pp)C (HSV target)
Preparation was carried out in an analogous manner to that in Example 56, starting from corresponding T(pp)T-CPG support from Example 4 instead of T(pp)T-CPG. In the condensation reactions, in step 4 the monomer building block of deoxyadenosine, deoxyguanosine or deoxycytidine corresponding to the sequence are in each case employed. Those commercially obtainable building blocks which have rapidly removable protective groups (®Expedite Fast Deprotecting Amidites; Millipore, Eschborn) are preferred.

Table 2

X	Nucl.	$\delta_{H\alpha}$ [ppm]	δ_{OH} [ppm]	$\delta_{C\alpha}$ [ppm]	δ_{31P} [ppm]
NMe_2	d4T	-	-	-	-
OCH_3	d4T	4.85	6.64	69.06/68.86 (1648Hz) (163.49Hz)	24.09/24.01
CH_3	d4T	4.95	6.30	69.50/69.10	23.84/23.81
H	d4T	4.975/5.01	6.35	69.53/69.35	23.72/23.64
Cl (MS=O.K.)	d4T	5.05	6.47	68.47	23.18/23.09
2,6-diCl	d4T	5.77	6.45	-	22.24/22.14
CN	d4T	5.19	6.64	68.99/68.90	22.41/22.32
4-NO_2	d4T	5.28	6.71	-	22.11/22.10
2-NO_2	d4T	6.06	6.83	-	21/72/21.65
2,4-diNO_2	d4T	7.13/7.09	6.13/6.11	-	20.21/20.46
2,6-diNO_2	d4T				
π	d4T	5.14	6.605	69.3	22.24/22.13
Octyl	d4T	3.74	5.55	-	27.86/27.82
NMe_2	ddT	4.885	6.08	69.2 (163.78Hz)	24.72/24.67
OCH_3	ddT	4.98	6.24	68.83 (165.72Hz)	24.28/24.25

X	Nucl.	$\delta_{H\alpha}$ [ppm]	δ_{OH} [ppm]	$\delta_{C\alpha}$ [ppm]	δ_{31P} [ppm]
CH_3	ddT	5.015	6.27	69.18 (159.06Hz)	24.09/24.06
H	ddT	5.056	6.355	69.33 (163.53Hz)	23.91/23.88
Cl	ddT	5.15	6.465	68.59 (164.016Hz)	23.38/23.35
2,6-diCl	ddT	5.82	6.67	67.64 (170.2Hz)	22.54/22.44
CN	ddT	5.25	6.63	68.77 (166.3Hz)	22.65/22.60
4-NO_2	ddT	5.32	6.69	68.74	22.44/22.40
2-NO_2	ddT	6.07	6.81	N.D.	22.12/22.10
2,4-NO_2	ddT	6.15	7.07	69.25	20.77/20.61
2,6-NO_2	ddT	N.D.	N.D.	N.D.	N.D.
π (MS O.K.)	ddT	5.17	6.67	67.55	22.51/22.49
Fluorenone	ddT	-	6.75	80.59 (165.71Hz)	23.37
NMe_2	AZT				
OCH_2	AZT				
CH_3	AZT				
H	AZT				
Cl	AZT				
CN	AZT				

X	Nucl.	δ_{H_2} [ppm]	δ_{OH} [ppm]	δ_{C_2} [ppm]	δ_{31P} [ppm]
4.NO_2	AZT	5.38	6.82	-	22.745 (DMSO)
2.NO_2	AZT	6.27	7.31	-	23.17/23.08 (MeOD)
2,6-NO_2	AZT	6.32	7.51	-	21.37/21.30 (MeOD)
2,4-diNO_2 (triester O.K. (MS O.K.))	AZT	6.16 [6.39]	7.173 [7.48]	- -	20.95/20.83 [21.57/21.38] MeOD)
π	AZT	5.22	6.69	-	22.79/22.76
Octyl (MS O.K.)	AZT	3.83	5.63	66.72	28.17/28.09

X	Nucleo. I	Nucleo. II	δ_{H_2} [ppm]	^{13}C [ppm]	δ_{OH} [ppm]	δ_{31P} [ppm]
2,6-diNO_2 triester O.K.	ddT	AZT	6.34	-	-	21.27/21.25 (MeOD) 21.23/21.17
2,6-di-NO_2 triester O.K.	d4T	AZT	6.29	-	7.22	20.38/20.28 (DMSO) 20.06/19.56
4-NO_2	d4T	AZT	5.32	-	6.78	22.63/22.20 (DMSO)
2-NO_2	ddT	d4T	6.01	-	6.86	22.24/22.23/ 21.71/21.40 (DMSO)
2-NO_2	3'T	d4T	6.15	-	6.86	22.37/22.15 (DMSO)
4-Cl	T	T	5.12	68.36(163.20Hz)	-	21.5/21.01/ 23.55/23.52 (DMSO)

REPLACEMENT SHEET (RULE 26)

X	Nucleo. I	Nucleo. II	δ_{H_6} [ppm]	^{13}C [ppm]	δ_{OH} [ppm]	δ_{31P} [ppm]
4-Cl	$T_{3'beo}$	$T_{3'beo}$	5.16	68.38 (163.30Hz)	6.58	23.68/23.66 (DMSO)
4-Cl	$T_{3'TBDMS}$	$T_{3'TBDMS}$	5.12	68.32 (163Hz)	N.D.	23.25/22.86 ($CDCl_3$)
4-Cl	$T_{3'Ac}$	$T_{3'Ac}$	5.16	68.49 (164.05Hz)	6.59	23.77/23.73 (DMSO)
4-OCH_3	$T_{3'Ac}$	$T_{3'Ac}$	5.05	68.72 (165.12Hz)	6.38	24.59/24.52 (DMSO)

H-Phosphonate diester and H-phosphonate monoester

Nucl. 1	Nucl. II	δ_H [ppm]	J_{HP} [Hz]	δ_{31P} [ppm]	LM
ddT	ddT	6.949	711.00	11.18	DMSO
ddT	-	6.815	637.01	7.24	D_2O
d4T	d4T	6.87	710.98	11.12	DMSO
d4T	-	6.71	637.67	7.07	D_2O
AZT	AZT	6.97	719.4	11.40	DMSO
AZT	-	7.02	674.54	1.06	DMSO
ddT	d4T	6.91	711.10	11.35/10.88	DMSO
ddT	AZT	6.939	736.51	11.35/11.26	DMSO
d4T	AZT	6.954	739.59	11.46/11.09	DMSO
$^{3'}$T	AZT	7.026	720.12	10.51/10.04	DMSO
$^{3'}$T	d4T	6.97	716.55	10.15/10.07	DMSO

REPLACEMENT SHEET (RULE 26)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Compounds of the formula I,



(I)

characterized in that

Y has the meaning of OH, SH, OAc or SAc, where Ac= (C1-C18)-acyl, which is optionally unsaturated 1-3 times,

R' is an aryl group having n carbon atoms which can be substituted or unsubstituted; or

an alkyl group having n carbon atoms, which can be branched or unbranched, substituted or unsubstituted; or a heteroaryl group which can have heteroatoms selected from the group including N,O and S, where n = any number of carbon atoms.

W has the meaning of a pharmaceutical active compound radical,

R has the meaning of W, where R and W can be identical or different, or R is an optionally substituted alkyl radical or

W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'



(II)



(II')

AUSTRALIAN PATENT OFFICE

where X is oxy, sulphanediyl or methylene,
B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 50,
R^1 and R^2 independently of one another are H (C1-C18) acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-18 carbon atoms,
R^3 is independently of one another H, O(C1-C18)-alkyl, O(C1-C18)-acyl, F, Cl, N_3, NH_2 or NHR^6 where R^6 is (C1-C6) - alkyl or -acyl
and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

2. Compounds of the formula I according to Claim 1, characterized in that
Y has the meaning of OH, SH, OAc or SAc, where Ac = (C1-C8) - acyl, which is optionally unsaturated 1-3 times,
R' is aryl having 6-14 carbon atoms, optionally substituted by up to three radicals which are independent of one another, selected from the group consisting of
(C1-C5) - alkyl, halogen, NO_2, CN, (C1-C6) - alkoxy, amino, (C1-C4)-alkylamino, (C1-C8) - dialkylamino, where a (C3 - C8) - alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 13 carbon atoms and up to 3 heteroatoms selected from the group consisting of N, O and S;
(C1-C16) - alkyl, which is branched or unbranched, optionally substituted independently of one another by up to three substituents selected from the group consisting of halogen, CN, NO_2 and (C1 - C3) - alkoxy, W has the meaning of a pharmaceutical active compound radical,

AUSTRALIAN PATENT OFFICE

R has the meaning of W, where R and W can be identical or different, or R is (C1-C16)-alkyl, which can be branched or unbranched and is optionally substituted independently of one another by up to 3 radicals from the group consisting of halogen, CN, (C1-C8)-acyloxy, (C1-C18)-alkoxy or W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'

where X is oxy or sulphanediyl,

B independently of one another is a nucleotide base,

n independently of one another is an integer from 0 to 30,

R^1 and R^2 independently of one another are H (C1-C12)-acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-12 carbon atoms,

R^3 independently of one another is H, O(C1-C12)-alkyl, O(C1-C12)-acyl, Cl, N_3, NH_2 or NHR^6 where R^6 is (C1-C3)-alkyl or -acyl

and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position,

3. Compounds of the formula I according to Claims 1 or 2,

characterized in that

Y has the meaning of OH, SH, OAc or SAc, where Ac = (C1-C3)-acyl, which is optionally unsaturated 1-3 times,

R' is aryl having 6-14 carbon atoms, optionally substituted by up to 3 radicals which are indepen-

dent of one another, selected from the group consisting of
(C1-C3)-alkyl, F, Cl, NO_2, CN, (C1-C4)-alkoxy, amino, (C1-C3)-alkylamino, (C1-C6)-dialkylamino, where a (C3-C8)-alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 6 carbon atoms and up to 3 heteroatoms selected from the group consisting of N, O and S;

(C1-C8) - alkyl, which is branched or unbranched, optionally substituted independently of one another by up to three substituents selected from the group consisting of Cl, CN, NO_2 and (C1-C3) - alkoxy,

W has the meaning of a 5'-, 3' or 2' nucleoside analogue, of a steroid, of a sugar, of an inositol or of a peptide having at least one amino acid Ser or Tyr and a total of up to 20 natural amino acids,
R has the meaning of W or is (C1-C8)-alkyl, which can be branched or unbranched and is optionally substituted by up to 2 radicals from the group consisting of halogen, CN, (C3-C6)-acyloxy, (C8-C18)-alkoxy or
W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'
where X is oxy,
B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 20,
R^1 and R^2 independently of one another are H (C1-C8)-acyl or a radical of the formula



AUSTRALIAN PATENT OFFICE

in which R^4 is O^-, S^-, CH_3 or $CHYR'$, where R' and Y are as defined above and R^3 is an optionally substituted alkyl radical having 1-8 carbon atoms,
R^3 independently of one another is H, O(C1-C8)-alkyl, O(C1-C8)-acyl, Cl or N_3, and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

4. Compounds of the formula I according to one or more of Claims 1-3,
characterized in that
Y has the meaning of OH,
R' is aryl having 6 carbon atoms, optionally substituted by up to 3 radicals which are independent of one another, selected from the group consisting of (C1-C3)-alkyl, F, Cl, NO_2, CN, (C1-C4)-alkoxy, amino, (C1-C3)-alkylamino, (C1-C6)-dialkylamino, where a (C3-C6)-alkylene radical in which a CH_2 group can also be replaced by oxy can also be fused onto the aryl radical;
heteroaryl having 3 to 6 carbon atoms and up to 3 heteroatoms selected from the group consisting of N, O and S;

(C1-C8) - alkyl, which is branched or unbranched, optionally substituted independently of one another by up to three substituents selected from the group consisting of Cl, CN, NO_2 and (C1-C3) - alkoxy,

W has the meaning of a 5'- or 3' nucleoside analogue,
R has the meaning of W or is (C1-C4)-alkyl, which can be branched or unbranched or
W and R, together with the phosphonate radical carrying them, form an oligonucleotide where W is a radical of the formula II and R is a radical of the formula II'
where X is oxy,

AUSTRALIAN PATENT OFFICE

B independently of one another is a nucleotide base,
n independently of one another is an integer from 0 to 15,
R^1 and R^2 independently of one another are H (C1-C4)-acyl or a radical of the formula



in which R^4 is O^-, S^-, CH_3 or CHYR', where R' and Y are as defined above and R^5 is an optionally substituted alkyl radical having 1-3 carbon atoms,
R^3 independently of one another is H, O(C1-C3)-alkyl, O(C1-C3)-acyl, Cl or N_3, and the curved bracket indicates that R^3 and the adjacent phosphonyl radical can be in the 2' or 3' position.

5. Compounds of the formula I according to one or more of Claims 1-4,
characterized in that
Y has the meaning of OH,
W has the meaning of a 5'- or 3' nucleoside analogue,
R has the meaning of W or is (C1-C4)-alkyl, which can be branched or unbranched,
R' is aryl having 6 carbon atoms, optionally substituted by up to 3 radicals which are independent of one another, selected from the group consisting of Cl, NO_2, CN, (C1-C3)-alkoxy, amino and (C1-C3)-alkylamino.

6. Process for the preparation of compounds according to one or more of Claims 1-5, characterized in that
a) a compound of the formula III is reacted with a compound of the formula IV,





(III)



(IV)

or in that

b) a compound of the formula V is reacted with compounds of the formula VI in any desired sequence and using a condensing agent,

or in that

c) a compound of the formula V is reacted with compounds of the formula VI and of the formula VII in any desired sequence and using a condensing agent,



(V)



(VI) (VII)

where SG is a protective group which is optionally removed to obtain the compound of the formula I,

or a nucleotide unit having a 3'(2')-terminal H-phosphonate group and protected 5'-hydroxy group is reacted with a further nucleotide unit having a free 5'-hydroxy group and protected 3'(2')-hydroxy group in the presence of an activating agent to give the H-phosphophosphonate dinucleoside and this is condensed with an aldehyde to give the dinucleoside α-hydroxy-alkyl (aryl) phosphonate, which after reaction to give its activated derivatives reacts with further (oligo) nucleotide fragments to give oligonucleotides, temporarily introduced protective groups being removed, or in that

a) a nucleotide unit having a 3' (2')-terminal phosphorus (III) or phosphorus (V) group is reacted with a free 5'-hydroxy group of a further nucleotide

unit or growing oligonucleotide chain in the presence of a condensing agent or

b) its activated derivatives, or the oligonucleotide analogue is built up in fragments in the same way, protective groups temporarily introduced into the oligonucleotides obtained according to a) or b) for the protection of other functions are removed and the oligonucleotide analogues of the formula I thus obtained in which W is a radical of the formula II and R is a radical of the formula II' are optionally converted into their physiologically tolerable salt.

7. Use of an oligonucleotide analogue according to any one of Claims 1 to 5 as an inhibitor of gene expression.

8. Pharmaceuticals, containing one or more of the compounds of the formula I according to any one of Claims 1-5.

9. A method of preparing a pharmaceutical including admixing at least one compound of the formula I as claimed in any one of Claims 1 to 5 with suitable excipients and/or carriers .

10. A method according to Claim 10 wherein said pharmaceutical has a prodrug function.

DATED this 23rd Day of July 1998

HOECHST AKTIENGESELLSCHAFT

WATERMARK PATENT & TRADEMARK ATTORNEYS
290 BURWOOD ROAD
HAWTHORN VICTORIA 3122
AUSTRALIA

AUSTRALIAN PATENT OFFICE

Abstract:

Methylphosphonic acid esters, processes for their preparation, and their use

From the compounds of the formula I,



(I) .

in which the substituents R', Y, W and R have the meanings mentioned, in vivo have the action of the active compound radical W together with improved pharmacokinetics.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: Hoechst Aktiengesellschaft
(B) STREET: -
(C) CITY: Frankfurt am Main
(D) FEDERAL STATE: -
(E) COUNTRY: Germany
(F) POSTAL CODE: 65926
(G) TELEPHONE: 069-305-6285
(H) TELEFAX: 069-357175
(I) TELEX: 41234700 hod

(ii) TITLE OF APPLICATION: Methylphosphonic acid esters, processes for their preparation, and their use

(iii) NUMBER OF SEQUENCES: 37

(iv) COMPUTER-READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPA)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: yes

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISMUS: HIV

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ACACCCAATT CTGAAAATGG
20

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HIV

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

AGGTCCCTGT TCGGGCGCCA
20

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HIV

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..28

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GTCGACACCG AATTCTGAAA ATGGATAA
28

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HIV

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCTATGTCGA CACCCAATTC TGAAA
25

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HIV

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 1..31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TCGTCGCTGT CTCCGCTTCT TCTTCCTGCC A
31

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HSV-1

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCGGGGCTCC ATGGGGGTCG
20

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: cytoplasmic/membrane-associated oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..15
(D) OTHER INFORMATION: /note= "c-Ha-ras"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CAGCTGCAAC CCAGC
15

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoprotein

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "c-myc"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGCTGCTGGA GCGGGGCACA C
21

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoprotein

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..15
(D) OTHER INFORMATION: /note= "c-myc"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AACGTTGAGG GGCAT
15

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..18
(D) OTHER INFORMATION: /note= "c-myb"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTGCCGGGGT CTTCGGGC
18

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid



(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "c-fos"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGAGAACATC ATGGTCGAAA G
21

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..22
(D) OTHER INFORMATION: /note= "c-fos"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CCCGAGAACA TCATGGTCGA AG
22

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "c-fos"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGGGAAAGCC CGGCAAGGGG
20

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "p120"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CACCCGCCTT GGCCTCCCAC
20

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: cellular receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..18
(D) OTHER INFORMATION: /note= "EGF receptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGGACTCCGG CGCAGCGC
18

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: cellular receptor

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "EGF receptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGCAAACTTT CTTTTCCTCC
20

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: p53 tumour suppressor

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GGGAAGGAGG AGGATGAGG
19

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) Length: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: p53 tumour suppressor

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GGCAGTCATC CAGCTTCGGA G
21

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..18
(D) OTHER INFORMATION: /note= "VLA-4"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GCAGTAAGCA TCCATATC
18

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "ICAM"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CCCCCACCAC TTCCCCTCTC
20

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "ICAM"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

CTCCCCCACC ACTTCCCCTC
20

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..19
(D) OTHER INFORMATION: /note= "ICAM"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GCTGGGAGCC ATAGCGAGG
19

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "ELAM-1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ACTGCTGCCT CTTGTCTCAG G
21

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: integrins or cell-cell adhesion receptors

(ix) FEATURES:

(A) NAME/KEY: exon

(B) LOCATION: 1..22

(D) OTHER INFORMATION: /note= "ELAM-1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CAATCAATGA CTTCAAGAGT TC

22

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:

(A) NAME/KEY: exon

(B) LOCATION: 1..18

(D) OTHER INFORMATION: /note= "c-myb"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GTGTCGGGGT CTCCGGGC
18

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..15
(D) OTHER INFORMATION: /note= "c-myc"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CACGTTGAGG GGCAT
15

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear transactivator proteins and cyclins

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..18
(D) OTHER INFORMATION: /note= "cdc2 kinase"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GTCTTCCATA GTTACTCA
18

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: nuclear oncoproteins

(ix) FEATURES:

(A) NAME/KEY: exon
(B) LOCATION: 1..18
(D) OTHER INFORMATION: /note= "PCNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GATCAGGCGT GCCTCAAA
18

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) ART: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: oligonucleotide

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..10
(D) OTHER INFORMATION: /note= "last nucleotide bond at the 3'-end is an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

TTTTTTTTTT

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..10
(D) OTHER INFORMATION: /note= "first nucleotide bond at the 5'-end is an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

TTTTTTTTTT

14

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(III) ANTI-SENSE: YES

(VI) ORIGINAL SOURCE:
(A) ORGANISM: HSV target

(IX) FEATURES:
(A) NAME/KEY: EXON
(B) LOCATION: 1..10
(D) OTHER INFORMATION: /NOTE= "first and last nucleotide bond is an α-hydroxy(o-nitrophenyl)methylphosphonate bridge"

(XI) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

TTTTTTTTTT
18

(2) INFORMATION FOR SEQ ID NO: 32:

(I) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(II) TYPE OF MOLECULE: DNA (GENOMIC)

(III) HYPOTHETICAL: YES

(III) ANTI-SENSE: YES

(IX) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "last

nucleotide bond at the 3'-end is an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GCAGGAGGAT GCTGAGGAGG C
25

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "first and last nucleotide bond is an α-hydroxy(o-nitrophenyl)methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GCAGGAGGAT GCTGAGGAGG C
29

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note= "1st, 11th and 20th nucleotide bond calculated from 5'-end is an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

GCAGGAGGAT GCTGAGGAGG C
33

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note= "first and last nucleotide bond is an α-hydroxy(o-nitrophenyl)methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GCGGGGCTCC ATGGGGGTCG
28

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: c-fos target

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..17
(D) OTHER INFORMATION: /note= "first and last nucleotide bond is an α-hydroxy(o-nitrophenyl)methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

CGAGAACATC ATGGTCG
25

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPES: DNA (genomic)

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HSV target

(ix) FEATURES:
(A) NAME/KEY: exon
(B) LOCATION: 1..22
(D) OTHER INFORMATION: /note= "last nucleotide bond at the 3'-end is an α-hydroxy(o-nitrophenyl)-methylphosphonate bridge"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

CGTCCATGTC GGCAAACAGC TC
26



INTERNATIONAL SEARCH REPORT

national Application No
PCT/EP 94/02121

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H21/00 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	CHEMICAL ABSTRACTS, vol. 120, no. 25, 20 June 1994, Columbus, Ohio, US; abstract no. 324093k, MEIER, C. '5',5'-O-Dinucleoside (alpha-hydroxybenzyl)phosphonates as a lipophilic potential prodrug of ddT' page 974 ; see abstract & ANGEW. CHEMIE vol. 105, no. 12 , 1993 pages 1854 - 6 ---	1-10
A	WO,A,93 10140 (PHARMAGENICS, INC.) 27 May 1993 Claims --- -/--	1-10

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 October 1994	16. 11. 94

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Bardill, W

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

national Application No
PCT/EP 94/02121

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TETRAHEDRON LETT. vol. 33 , 1992 pages 2357 - 60 ROELEN, H. 'Synthesis of Alkylphosphon(othio)ate Analogues of DNA' see the whole document	1-10
A	BIOORG. MED. CHEM. LETT. vol. 1 , 1991 pages 527 - 30 MEIER, C. 'O-Alkyl-5',5'-dinucleoside-phosphates as combined prodrugs of antiviral and antibiotic compounds' see the whole document	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

ational Application No
PCT/EP 94/02121

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9310140	27-05-93	NONE	

INTERNATIONALER RECHERCHENBERICHT

nationales Aktenzeichen
PCT/EP 94/02121

A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES
IPK 6 C07H21/00 A61K31/70

Nach der Internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

B. RECHERCHIERTE GEBIETE

Recherchierter Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)
IPK 6 C07H A61K

Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

C. ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
P,X	CHEMICAL ABSTRACTS, vol. 120, no. 25, 20. Juni 1994, Columbus, Ohio, US; abstract no. 324093k, MEIER, C. '5',5'-O-Dinucleoside (alpha-hydroxybenzyl)phosphonates as a lipophilic potential prodrug of ddT' Seite 974 ; siehe Zusammenfassung & ANGEW. CHEMIE Bd. 105, Nr. 12 , 1993 Seiten 1854 - 6 ---	1-10
A	WO,A,93 10140 (PHARMAGENICS, INC.) 27. Mai 1993 Claims --- -/--	1-10

[X] Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

[X] Siehe Anhang Patentfamilie

* Besondere Kategorien von angegebenen Veröffentlichungen :
"A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist
"E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist
"L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)
"O" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht
"P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist
"T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist
"X" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderischer Tätigkeit beruhend betrachtet werden
"Y" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderischer Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist
"&" Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der internationalen Recherche	Absendedatum des internationalen Recherchenberichts
13. Oktober 1994	16. 11. 94

Name und Postanschrift der Internationalen Recherchenbehörde	Bevollmächtigter Bediensteter
Europäisches Patentamt, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Bardili, W

Formblatt PCT/ISA/210 (Blatt 2) (Juli 1992)

INTERNATIONALER RECHERCHENBERICHT

nationales Aktenzeichen
PCT/EP 94/02121

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
A	TETRAHEDRON LETT. Bd. 33 , 1992 Seiten 2357 - 60 ROELEN, H. 'Synthesis of Alkylphosphon(othio)ate Analogues of DNA' siehe das ganze Dokument ---	1-10
A	BIOORG. MED. CHEM. LETT. Bd. 1 , 1991 Seiten 527 - 30 MEIER, C. 'O-Alkyl-5',5'-dinucleoside-phosphates as combined prodrugs of antiviral and antibiotic compounds' siehe das ganze Dokument -----	1-10

1

INTERNATIONALER RECHERCHENBERICHT

Angaben zu Veröffentlichungen, die zur selben Patentfamilie gehören

nationales Aktenzeichen
PCT/EP 94/02121

Im Recherchenbericht angeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
WO-A-9310140	27-05-93	KEINE	